The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter, phase 1 study of AB011, a recombinant humanized anti-CLDN18.2 monoclonal antibody, as monotherapy and combined with capecitabine and oxaliplatin (CAPOX) in patients with advanced solid tumors.
 
Jin Li
No Relationships to Disclose
 
Hongming Pan
No Relationships to Disclose
 
Tianshu Liu
No Relationships to Disclose
 
Nong Xu
No Relationships to Disclose
 
Yanqiao Zhang
No Relationships to Disclose
 
Yanru Qin
No Relationships to Disclose
 
Jianhua Shi
No Relationships to Disclose
 
Dongcheng Liao
No Relationships to Disclose
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squib; Daiichi Sankyo; Harbour BioMed; Merck; Mingji biopharmaceutical; MSD; Roche
Speakers' Bureau - Hutchison Whampoa; MSD
Research Funding - Baiji Shenzhou (Beijing) Biotechnology (Inst); Beijing Xiantong Biomedical Technology (Inst); Nanjing Yaojieankang Biotechnology (Inst); QiLu Pharmaceutical (Inst); Zaiding Pharmaceutical (Inst)
 
Suxia Luo
No Relationships to Disclose
 
Yueyin Pan
No Relationships to Disclose
 
Wei Zhao
No Relationships to Disclose
 
Yu Zheng
No Relationships to Disclose
 
Rongyuan Zhuang
No Relationships to Disclose
 
Chenyu Mao
No Relationships to Disclose
 
Yue Ma
No Relationships to Disclose
 
Huamao Wang
Employment - CARsgen Therapeutics
Leadership - CARsgen Therapeutics
Stock and Other Ownership Interests - CARsgen Therapeutics
 
Zonghai Li
Employment - CARsgen Therapeutics
Leadership - CARsgen Therapeutics
Stock and Other Ownership Interests - CARsgen Therapeutics
Patents, Royalties, Other Intellectual Property - CARsgen Therapeutics